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Anti-Retroviral Therapy (ART) is the recommended first line therapy for patients with HIV. Since 
2004, Chinese government has provided free Chinese herbal medicine (CHM) for Chinese HIV/AIDS 
patients. Data of living patients with HIV from the NFTCMP database and Center for Disease Control 
(CDC) database during 2003–2016 in Guangxi province was obtained and compared. Patients were 
divided into 3 groups according to their recorded treatment regimens. A total of 2954 patients with 
their treatment recorded in the two databases were included for analysis, their median age was 
46 years (IQR = 36–59), and 64.63% were male. CHM regimens users had baseline CD4 cell counts 
(380.11 ± 240.59 cell/μL), approximately 100 cell/μL significantly higher than patients receiving CHM 
combined with ART regimens or only ART regimens. There was no significant difference in mortality 
among groups. All three regimens improved patients’ CD4 cell counts. Compared to the sharp 
improvement in ART group during the first 6 months, CD4 cell counts of patients in CHM group and CHM 
combined with ART group showed a smooth and steady rise. CD4 cell counts of the combined group 
remained much lower than ART group in the first 3 years, but overtook ART group in the fourth year.
Human immunodeficiency virus (HIV) is a retrovirus that can destroy or impair the function of the immune 
system and which can later progress to Acquired Immune Deficiency Syndrome (AIDS), the most advanced stage 
of HIV infection. HIV/AIDS remains one of the most important public health problems in the world, particularly 
in low-income and middle-income countries. According to the World Health Organization (WHO) report1, at 
the end of 2015, there were 36.7 million [34.0 million–39.8 million] people living with HIV, and more than 18 
million people were receiving antiretroviral treatment (ART) by mid-2016. Due to treatment, the global annual 
HIV-related all-cause mortality has continually decreased in recent years. By 2015 the number had reduced to 
1.1 million [940 000–1.3 million]. According to the recent report of China Centers for Disease Control (CDC), 
on October 31, 2017, China’s population of people living with HIV was about 750,0002. HIV/AIDS remains one 
of the most important public health problems in China and no longer restricted to blood donors and drug users 
but increasingly spreading through the general population due to unsafe sex, especially among men who have 
had sex with men3–5.
Chinese herbal medicine (CHM) was firstly used to treat patients living with HIV in 1987 when Chinese 
medicine practitioners from China provided medical assistance in Tanzania, Africa6. In China, there are three 
main strategies for treating HIV, which include ART alone, CHM alone, and CHM combined with ART. A pilot 
project, the National Free CHM HIV/AIDS Treatment Program (NFCHMP), was initiated in 2004 and expanded 
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rapidly. NFCHMP was supported by the State Administration of Traditional Chinese Medicine (SATCHM) and 
the Ministry of Finance, and the program has provided tens of thousands of HIV/AIDS patients with free Chinese 
medicine treatment.
A double-blind randomized controlled trial7 found CHM could significantly improve CD4 cell counts and 
symptoms (anorexia, diarrhea, fatigue, nausea, and emesis). In Henan province, a retrospective cohort study 
based on the database of NFCHMP observed CHM could decrease the disease progression, reduce the mortality 
of PLHIV, and improve life expectancy. However, the major limitation was that they chose the world mortality 
rate over the same period as a comparison8. A 7-year observational study suggested long-term use of CHM could 
maintain or slow the pace of CD4 cell counts declining. However, this study did not address bias, potential con-
founders and the possibility that results may have occurred by chance9. CHM has also been reported to relieve 
HIV/AIDS patients’ clinical symptoms (e.g., fatigue, pain, sleep disturbance, shortness of breath, coughing) and 
significantly decrease opportunistic infections in before and after studies10–12. Although there is some evidence 
to indicate there was an observable effect of CHM therapy on HIV, most studies had a small sample size and did 
not address confounding factors. To confirm the effect and safety of CHM, analysis of more longitudinal data is 
required to analyze the characteristics of the patients who receive CHM therapy, and statistically adjust for con-
founding factors. Obtaining longitudinal data is expensive, time-consuming, and the data is difficult to analyze, 
the advantage of longitudinal data is that the individual development of a certain outcome variable can be studied 
over time. However, when evaluating the effect of CHM for HIV/AIDS, most studies have ignored individual dis-
ease progression. With the development of statistical techniques, such as generalized estimating equations (GEE) 
and random coefficient analysis, it has become possible to analyze longitudinal relationships using all available 
longitudinal data, without summarizing the longitudinal development of each subject into one value13.
Guangxi, a province located in southwestern China that borders Myanmar, has the second highest HIV prev-
alence in the whole country due to its specific geographical location and cultural environment14. Therefore, this 
study aimed to utilize and explore longitudinal data from the registries established by SATCHM in Guangxi 
province to analyze the effect of CHM on patients with HIV.
Methods
Data sources. The Ethics Committee of Beijing University of Chinese medicine granted ethical approval 
for analyzing data from two registries (BZYYYDX-LL20160215). This study complied with the Declaration of 
Helsinki and Good Clinical Practice Guidelines in China. All participants provided their written informed con-
sent and allowed their medical data to be used for researches. To protect participants’ privacy, we extracted all 
available data without names and other identifiers on HIV patients from two registries (CHM registry and CDC 
registry) in Ruikang Hospital, which is located in the Guangxi province of southern China. We excluded 29 
records that only had an ID number and had no other information.
CHM database collected data HIV/AIDS patients who participated in the NFCHMP and received CHM ther-
apy. In this registered database, all participants were identified from 16 clinical centers across 14 cities. The CDC 
database in Nanning, the capital of Guangxi province, was also included to compare the effectiveness of CHM 
therapy and ART therapy. All patients in the two registries had been diagnosed with HIV infection via virus 
detection.





(n = 1194) P value
Marital status— no. (%)
Single 414 (16.38%) 240 (18.00%) 174 (14.57%) <0.01
Married 1640 (64.9%) 854 (64.07%) 786 (65.83%)
Divorced 180 (7.12%) 108 (8.10%) 72 (6.03%)
widowed 293 (11.59%) 131 (9.83%) 162 (13.57%)
Educational levels— no. (%)
College graduate 113 (4.46%) 63 (4.72%) 50 (4.18%) <0.01
Senior high school 276 (10.9%) 135 (10.11%) 141 (11.79%)
Junior middle school 1060 (41.88%) 540 (40.45%) 520 (43.48%)
Elementary school 887 (35.05%) 467 (34.98%) 420 (35.12%)
Unschooled 40 (1.58%) 26 (1.95%) 14 (1.17%)
Preschool 155 (6.12%) 104 (7.79%) 51 (4.26%)
possible HIV-infected route
Blood transfusion 8 (0.31%) 5 (0.37%) 3 (0.25%) <0.01
Drug taking 294 (11.57%) 145 (10.79%) 149 (12.44%)
Sexual behavior 2172 (85.44%) 1134 (84.38%) 1038 (86.64%)
Mother-to-child transmission 12 (0.47%) 5 (0.37%) 7 (0.58%)
Paid blood donation 7 (0.28%) 2 (0.15%) 5 (0.42%)
Unclear 130 (5.11%) 83 (6.18%) 47 (3.92%)
Table 1. Baseline demographic characteristics of the CHM database stratified by therapy.
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Procedure. In the 16 NFCHMP clinical centers, the patients diagnosed with HIV infection would have been 
informed that NFCHMP could provide free CHM. Patients who had a previous record of severe cerebrovascular 
disease, severe kidney and hematopoietic system disease, and mental disease were excluded. The NFCHMP par-
ticipants would have been registered on the CHM registry and would have completed the pre-CHM treatment 
examination, which we defined as a baseline.
Participants were provided with medication and assessed every three months via an interview and labo-
ratory testing. Doctors identified the CHM therapy according to the infection stage of patients and used the 
Clinical practice proposal of Traditional Chinese medicine treatment for patients living with HIV/AIDS issued 
by SATCM. CHM therapy could include Chinese patent medicines such as Tangcao tablets, Shenling Fuzheng 
capsules, Qingdu capsules, Aifukang capsules, as well as other herbal recipes, depending on patients’ symptoms 
and according to TCM hospital clinical practice. Whether to take a combined treatment of CHM and ART were 
decided based on patients’ wishes and symptoms.
Index ALL (n = 2637) CHM (n = 1180)
CHM combined 
ART (n = 1126) ART (n = 331) P value
Sex—no. (%)
n 2486 1125 1053 343 <0.01
Male 1622 (65.25%) 694 (63.32%) 716 (68.06%) 212 (62.72%)
Female 864 (34.75%) 402 (36.68%) 336 (31.94%) 126 (37.28%)
Age–yr
n 2473 1099 1053 321 <0.01
Mean ± Std 47.35 ± 14.24 47.41 ± 14.74 47.97 ± 13.00 45.12 ± 16.13
Median 45 45 46 40
IQR 36, 59 36, 59 37, 59 33, 57
Range 17–88 17–88 19–84 20–88
Age group — no. (%)
n 2473 1099 1053 321 <0.01
<20 yr 6 (0.24%) 5 (0.45%) 1 (0.09%) 0 (0%)
20–29 yr 215 (8.69%) 114 (10.37%) 52 (4.94%) 49 (15.26%)
30–39 yr 647 (26.16%) 261 (23.75%) 283 (26.88%) 103 (32.09%)
40–49 yr 579 (23.41%) 260 (23.66%) 264 (25.07%) 55 (17.13%)
50–59 yr 428 (17.31%) 193 (17.56%) 193 (18.33%) 42 (13.08%)
60–69 yr 433 (17.51%) 181 (16.47%) 211 (20.04%) 41 (12.77%)
> =70 yr 165 (6.67%) 85 (7.73%) 49 (4.65%) 31 (9.66%)
CD4— cell/μL
n 2520 1124 1053 343 <0.01
Mean ± Std 316.85 ± 199.19 376.80 ± 213.53 271.45 ± 181.54 258.17 ± 133.01
Median 286 372 237 255
IQR 177, 424 371 237 166, 348
Range 1–1538 235.5, 488.5 148, 347 1–773
CD4 group — no. (%)
n 2521 1125 1053 343 <0.01
<350 cell/μL 1551 (61.52%) 499 (44.36%) 794 (75.40%) 258 (75.22%)
≥350 cell/μL 970 (38.48%) 626 (55.64%) 259 (24.60%) 85 (24.78%)
CD8— cell/μL
n 2154 1206 943 3 <0.01
Mean ± Std 956.31 ± 521.66 1057.74 ± 550.32 848.67 ± 466.63 778.33 ± 34.96
Median 860.5 977.5 758 797
IQR 586, 1223 682, 1344 530, 1079 738, 800
Range 0–4531 0–4416 48–4531 738–800
Platelets—×109/L
n 2637 1180 1126 331 <0.01
Mean ± Std 224.94 ± 74.87 220.45 ± 76.22 233.75 ± 72.71 216.23 ± 73.80
Median 219 214 226 209
IQR 179, 266 171, 259 189, 275 177, 248
Range 0.26–792 2.9–792 0.26–600 14–593
Hemoglobin—(g/L)
n 2637 1180 1126 331 0.56
Table 2. Baseline demographic and clinical characteristics of the whole cohort stratified by therapy.
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According to the CHM registry, all patients took CHM. To compare the effectiveness of CHM with ART, we 
also accessed the CDC registry and extracted the data of HIV patients who took ART alone in Ruikang hospital.
Outcome measures. Demographic characteristics included participants’ gender and age were recorded in 
two registries. CHM registry recorded more demographic information, including marital status, educational lev-
els, and possible route of infection. Mortality rate, CD4, CD8 cell counts, and white blood cell (WBC) counts were 
extracted to evaluate the effectiveness. We used the abnormal rate of liver and kidney function to evaluate safety. 
Alanine transaminase (ALT) and aspartate aminotransferase (AST) were used to evaluate liver function. Blood 
urea nitrogen (BUN) and creatinine (Cr) were used to evaluate kidney function.
Statistics. The data analyses were performed using SAS version 9.4. We divided participants into different 
groups by treatment. At baseline, descriptive statistics were used to examine the demographic and clinical char-
acteristics of all participants and in different groups. Continuous variables were summarized as means, standard 
deviations, median, interquartile range (IQR), range (minimum value to maximum). For categorical variables, 
the number and percentages of patients in each category were calculated and the proportions of participants who 
had dropped out, and the meantime of drop-out.
This study provided longitudinal data, in which the outcome variables were repeatedly measured. We used 
analysis of covariance (ANCOVA) and GEE statistical methods to adjust confounding factors13.
Our first approach was an analysis of changes in outcomes between two points in time. Differences between 
groups were tested for statistical significance using chi-square and Wilcoxon-Mann-Whitney tests for categori-
cal and continuous variables, respectively. Besides, differences between groups were estimated using a one-way 
analysis of variance (ANOVA) followed by the Student-Newman-Keuls (SNK) test for all pairwise comparisons. 
Results were considered statistically significant at 0.05 p-value.
ANCOVA used to adjust confounding factors (gender, age, CD4 cell counts at baseline), furthermore, we used 
GEE to investigate the relationship between the outcome variable CD4 cell counts and the predictor variables 
(gender, age, group and time), and in the model used in this study, we assumed a linear relationship with time.
Ethical approval and informed consent. The Ethics Committee of Beijing University of Chinese medi-
cine granted ethical approval for the study.
Results
Demographic characteristics. Two thousand nine hundred fifty-four individuals recorded in two regis-
tries were extracted for analyses. Of these, 1374 individuals used CHM alone, 1198 individuals used CHM com-
bined with ART, and 382 individuals used ART alone. Participants registered on the databases between 2003 and 
2016, the highest proportion (25.84%) were in 2013.
One hundred ten patients dropped out from CHM alone group with the mean drop-out time of 9.11 months. 
Reasons for dropping out were migrating from the area for work (n = 11), unwilling to take medications (n = 24), 
patients voluntarily withdrawing from the project (n = 39), travel issues (n = 4), other reasons including: lost 
touch, compulsory detoxification, being put in prison (n = 32).
Sixty-seven patients dropped out from CHM combined with ART group, and the meantime of drop-out was 
17.78 months. They dropped out for the following reasons: migrating from the area for work (n = 3), unwilling to 
take medications (n = 21), patients voluntarily withdrawing from the project (n = 23), travel issues (n = 4), other 
reasons including compulsory detoxification and lost-to-follow-up (n = 16).
Of the participants who used CHM therapy and provided demographic characteristics, most participants were 
married (64.07%), 18.00% were single, 8.10% were divorced, and it is noted that 9.83% were widowed. Further 
analysis found that, for female patients, the proportion of the widowed (16.86%) was much higher than that 
of the single (7.58%). On the contrary, for males, the proportion of those who were single (21.24%) was much 
higher than that of widowed (8.75%). Most participants (40.45%) only received junior middle school education, 
Figure 1. CD4 cell counts curves through 4-years for 3 cohorts stratified by therapy.
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and few (4.72%) had college or further college education. Most participants (84.38%) considered their possible 
HIV-infected route was sexual behavior, and drug taking (10.79%) was the second leading possible infection 
route (Table 1). Individuals used CHM combined with ART had similar but slightly different demographic char-
acteristics. The demographic characteristics of the CHM group and CHM combined with ART group could be 
compared, but the CDC registry (individuals used ART alone) did not record information on the potential infec-
tion route.
Index CHM (n = 1180)
CHM combined ART 
(n = 1126) ART (n = 331)
Adjusted P 
value
change from baseline values at 0.5-yr
n 476 436 15 0.26
Mean ± Std 6.47 ± 184.19 31.68 ± 123.94 91.87 ± 121.31
95% CI [−10.12, 23.06] [20.02, 43.35] [24.69, 159.05]
Median 0.5 21 42
IQR −90, 95 −17, 83 4, 196
change from baseline values at 1-yr
n 337 344 201 <0.01
Mean ± Std 15.9 ± 192.33 60.35 ± 130.26 130.2 ± 112.41
95% CI [−4.71, 36.51] [46.53, 74.16] [114.57, 145.84]
Median 9 43 122
IQR −85, 141 −14, 122.5 58, 210
change from baseline values at 1.5-yr
n 277 206 179 <0.01
Mean ± Std 30.03 ± 175.55 72.39 ± 117.36 158.07 ± 132.15
95% CI [9.26, 50.79] [56.27, 88.51] [138.58, 177.57]
Median 32 65 150
IQR −88, 160 5, 131 59, 228
change from baseline values at 2-yr
n 202 147 152 <0.01
Mean ± Std 49.16 ± 198.09 72.12 ± 165.72 198.84 ± 158.79
95% CI [21.68, 76.65] [45.1, 99.13] [173.39, 224.29]
Median 57.5 59 176
IQR −93, 189 −2, 169 97.5, 267
change from baseline values at 2.5-yr
n 139 105 123 <0.01
Mean ± Std 70.68 ± 226.16 91.61 ± 166.55 208.91 ± 164.85
95% CI [32.75, 108.61] [59.38, 123.84] [179.49, 238.33]
Median 62 85 187
IQR −78, 201 3, 180 118, 280
change from baseline values at 3-yr
n 106 115 82 <0.01
Mean ± Std 49.08 ± 214.89 107.9 ± 176.79 214.91 ± 152.34
95% CI [7.69, 90.46] [75.24, 140.55] [181.44, 248.39]
Median 46.5 100 197
IQR −76, 164 29, 189 111, 298
change from baseline values at 3.5-yr
n 63 71 53 0.10
Mean ± Std 93.79 ± 288.11 111.17 ± 161.89 210.75 ± 168.62
95% CI [21.24, 166.35] [72.85, 149.49] [164.28, 257.23]
Median 122 110 195
IQR −59, 226 35, 207 100, 303
change from baseline values at 4-yr
n 52 59 31 0.68
Mean ± Std 116.15 ± 229.04 146.63 ± 228.8 231.48 ± 182.6
95% CI [52.39, 179.92] [87, 206.25] [164.5, 298.46]
Median 63.5 112 199
IQR −62.5, 273 33, 224 112, 335
Table 3. CD4 cell counts of the whole cohort stratified by therapy.
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After data filtering, we analyzed 2637 patients with effective or safety information. The average age of the 
whole sample was 47.35 ± 14.24, the median age was 45 years (IQR = 36–59), and 65.25% were male (Table 2).
Effectiveness evaluation. During the study period, there were no statistical differences between the groups 
in mortality (p = 0.24). Seven patients (0.51%) in the CHM group, eight patients (0.67%) in CHM combined with 
ART group, and five patients (1.31%) in the ART group, died.
The baseline clinical characteristics of the whole cohort were stratified by therapy (Table 2). At baseline, there 
were significant differences across the three groups regarding age and sex. However, all three were more likely 
to contain male patients and patients were mostly 30 to 49 years old. CHM regimens users had better baseline 
status of CD4 cell counts (376.80 ± 213.53 cell/μL, median 371, IQR = 235.5–488.5 cell/μL), around 100 cell/μL 
higher than the patients with CHM combined with ART regimens (271.45 ± 181.54, median 237, IQR = 148–347 
cell/μL) and ART regimens (258.17 ± 133.01, median 255, IQR = 166–348 cell/μL), and there was no significant 
difference between CHM combined with ART group and ART group. Participants were categorized according to 
whether the CD4 cell count was greater than 350 per μL. The CHM group had a significantly higher proportion 
(55.64%) of participants with higher CD4 counts when compared to CHM combined with ART group (24.60%) 
and ART group (24.78%).
Changes in CD4 cell counts of the three cohorts were explored. As most participants had been registered in 
databases since 2011, four years of data were available. Figure 1 reflected the change curves of CD4 cell counts 
over a 48-months period for all three groups. All three regimens demonstrated improvements in patients’ CD4 
cell counts. Compared to the initial sharp improvement in the ART group, the CD4 cell counts of patients 
in CHM group and CHM combined with ART group rose steadily and smoothly and respectively peaked at 
499.49 ± 199.25 (median 502, IQR = 365–620) and 438.38 ± 200.68 (median 412.5, IQR = 305–535) cell/μL by 
48 months. Compared to CHM group and CHM combined with ART group, participants used ART alone had 
rapidly increasing CD4 cell counts when treatment was initiated and was more likely to slow down their improve-
ment of CD4 cell counts after six months. In the ART group, CD4 cell counts reached a peak at 36 months, before 
beginning its gradual decline to 414.15 ± 213.68 (median 386.5, IQR = 255–477) cell/μL in 48 months.
We calculated the change of CD4 cell counts from baseline value during the 4-years follow-up period, 
ANCOVA was used to adjust major confounding factors (age, sex) and compared the differences among groups 
(Table 3).
Table 4 shows the results of a GEE analysis that was applied to investigate the relationship between the out-
come variable CD4 cell counts and the four predictor variables, including gender, age, group, and time. For each 
of the predictor variables the regression coefficient, the standard error of the coefficient and the corresponding 
p-value were given. In this model, time was added as a continuous variable coded as [1 to 15], and respectively 
corresponded to the baseline and the 16 follow-ups during four years.
Gender was significantly related to the development of outcome variable CD4 cell counts. The regression 
coefficient (β = 48.73, p < 0.01) for gender indicates that there was a greater increase in CD4 counts for females 
over time. For age, a negative association was found (β = −2.11, p < 0.01). The results also showed that there was 
a significant linear increase over time in CD4 cell counts (β = 9.43, p < 0.01). The change in CD4 over time was 
significantly different among groups.
Table 5 shows the laboratory data for each cohort. CD8 cell counts were compared between the three groups 
by adjusting for age, sex, and baseline values, and there was no significant difference detected during the first 
4-year follow-up periods except the 2.5-year.
At baseline, comparing to participants used ART alone (5.16 ± 1.73, median 4.97, IQR = 3.97–6.1 × 109/L), 
participants in CHM group (5.71 ± 1.85, median 5.4, IQR = 4.55–6.53 × 109/L) and CHM combined with ART 
group (5.5 ± 2.26, median 5.2, IQR = 4.1–6.54 × 109/L) were more likely to have higher white blood cell (WBC) 
counts. After one year of treatment, there were no statistical differences in WBC counts among groups, and the 
mean and median WBC counts were all within normal limits.
Safety evaluation. Figure 2 shows the abnormal rate of liver and kidney function throughout the 4-years 
for the three groups. For liver function, at baseline, the abnormal rate of AST in CHM combined with ART group 
(19.79%) was significantly (χ2 = 7.73, P = 0.02) higher than the ART group (13.61%). The abnormal rate of ALT 
had significant differences among groups. In the first three months of ART treatment, liver function abnormal 
rate significantly increased and significantly higher than the other two treatments. However, after more than three 
months of treatment, no significant difference was detected among groups. Regarding kidney function, BUN and 
Cr were not significantly different at baseline between the groups. For patients taking CHM and CHM combined 
with ART, and ART, the baseline BUN abnormal rate was 4.54%, 4.06%, and 4.56% respectively. There was no 
significant difference. During four years of treatment, only at 48 months was a significant difference detected 
Parameter Estimate Standard Error 95% Confidence Limits Z P
Intercept 466.64 17.18 [432.97, 500.32] 27.16 <0.01
gender 48.73 7.42 [34.20, 63.27] 6.57 <0.01
age −2.11 0.25 [−2.59, −1.62] −8.50 <0.01
group −35.43 5.16 [−45.54, −25.33] −6.87 <0.01
time 9.43 0.48 [8.48, 10.38] 19.50 <0.01
Table 4. Results of a GEE analysis.
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Index CHM (n = 1180)
CHM combined ART 





n 534 462 15 0.09
Mean ± Std 1026.54 ± 577.33 796.59 ± 465.24 1147.93 ± 631.31
Median 938 677.5 853
IQR 639, 1304 481, 1058 756, 1887
Range 0.54–6548 0.4–3936 332–2303
1-yr
n 395 368 212 0.80
Mean ± Std 962.73 ± 503.06 796 ± 448.57 902.25 ± 403.66
Median 878 698.5 838.5
IQR 595, 1296 465.5, 1010.5 622.5, 1102
Range −919–3571 3.92–2710 169–2557
1.5-yr
n 334 221 187 0.96
Mean ± Std 988.15 ± 494.44 903.42 ± 464.63 897.03 ± 452.45
Median 892.5 782 817
IQR 606, 1339 575, 1201 593, 1078
Range 136–2638 97–2723 150–2819
2-yr
n 253 161 160 0.86
Mean ± Std 950.55 ± 492.02 881.84 ± 488.51 964.44 ± 478.43
Median 879 767 869
IQR 585, 1226 557, 1039 645.5, 1144
Range 8.4–2840 174–3578 227–2833
2.5-yr
n 194 119 126 <0.05
Mean ± Std 951.74 ± 498.61 851.51 ± 501.46 975 ± 434.36
Median 836.5 740 940
IQR 581, 1224 571, 1090 639, 1191
Range 0.42–2800 6.07–3990 243–2506
3-yr
n 146 125 81 0.23
Mean ± Std 944.08 ± 523.42 811.51 ± 457.71 985 ± 493.67
Median 829 719 855
IQR 551, 1194 475, 957 640, 1226
Range 96–2518 115–2705 343–2955
3.5-yr
n 97 76 53 0.57
Mean ± Std 907.46 ± 438.55 839.16 ± 406.26 916.64 ± 377.64
Median 782 761 794
IQR 577, 1110 535.5, 1052.5 642, 1100
Range 299–2157 218–1976 349–1768
4-yr
n 87 66 34 0.96
Mean ± Std 914.8 ± 452.13 882.45 ± 609.46 942.21 ± 538.44
Median 817 731.5 811
IQR 585, 1204 563, 988 516, 1187
Range 127–2289 282–4318 332–2828
White blood cell—×109/L
0.5-yr
n 785 735 292 <0.01
Mean ± Std 5.64 ± 1.69 5.48 ± 1.74 5.06 ± 1.63
Median 5.4 5.3 4.91
IQR 4.55, 6.51 4.37, 6.4 3.96, 6.18
Range 0.75–16.2 1.67–14.4 1.82–11.44
Continued
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between CHM combined with ART and ART alone. Three groups had similar Cr at baseline. During the treat-
ment, the abnormal rate for the CHM group was significantly higher than for the CHM combined with ART at 3 
months. Additionally, at 33 months, CHM had a significantly higher abnormal rate than ART.
Discussion
This preliminary analysis showed that CHM gradually and continuously improved CD4 cell counts of patients 
with a relatively better baseline CD4 status. Compared to patients who only took the ART regimen, the patients 
who combined CHM were more likely to have a steady and continuous growth in CD4 cell counts. This phenom-
enon indicated there might be some drug interactions between two therapies. We found that for the patients who 
had relatively higher CD4 cell counts (>350 cell/μL) and did not take ART before, CHM could steadily increase 
CD4 cell counts and improved immunity levels. Compared to using ART alone, the CD4 cell counts of partici-
pants using CHM combined with ART increased slower in the first three years. It may relate to the potential effect 
of CHM on promoting immune reconstitution and counteracting the adverse side effects of antiviral drugs15. A 
study has suggested that the asymptomatic stage is the optimal time to take CHM, for it could help to maintain 
Index CHM (n = 1180)
CHM combined ART 




n 610 619 252 <0.05
Mean ± Std 5.62 ± 1.75 5.46 ± 1.79 5.3 ± 1.61
Median 5.39 5.15 5.1
IQR 4.42, 6.48 4.23, 6.4 4.18, 6.23
Range 1.72–18.7 2.06–15.8 1.45–11.53
1.5-yr
n 492 357 252 0.51
Mean ± Std 5.69 ± 1.64 6.39 ± 15.78 5.3 ± 1.61
Median 5.44 5.38 5.1
IQR 4.43, 6.63 4.39, 6.42 4.18, 6.23
Range 1.5–12.4 1.89–301 1.45–11.53
2-yr
n 390 296 199 0.59
Mean ± Std 5.61 ± 1.6 6.49 ± 17.65 5.78 ± 3.56
Median 5.45 5.32 5.37
IQR 4.5, 6.5 4.39, 6.35 4.51, 6.47
Range 2.46–11.8 2.23–308 2.09–50.2
2.5-yr
n 309 229 178 0.38
Mean ± Std 5.66 ± 1.71 5.69 ± 1.88 5.47 ± 1.53
Median 5.4 5.44 5.31
IQR 4.4, 6.71 4.4, 6.59 4.46, 6.3
Range 2.7–13.07 2–16.66 2.4–10.89
3-yr
n 219 169 129 0.59
Mean ± Std 5.62 ± 1.57 5.55 ± 1.8 5.56 ± 1.62
Median 5.47 5.27 5.41
IQR 4.5, 6.6 4.2, 6.5 4.62, 6.23
Range 2.33–11.3 2.21–11.9 2.25–11.78
3.5-yr
n 163 129 84 0.10
Mean ± Std 5.47 ± 1.68 5.28 ± 1.54 5.49 ± 1.6
Median 5.3 4.94 5.31
IQR 4.4, 6.2 4.2, 6.08 4.18, 6.32
Range 2.79–14.68 2.2–10.9 2.59–9.95
4-yr
n 125 94 57 0.35
Mean ± Std 8.92 ± 36.02 5.97 ± 1.79 5.29 ± 1.44
Median 5.5 5.57 5.26
IQR 4.71, 6.3 4.7, 7 4.44, 5.96
Range 2.48–408 3–12.1 2–9.99
Table 5. Laboratory indexes of the whole cohort stratified by therapy.
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and enhance the immune function so as to delay the progression to the AIDS stage. For those patients who 
have a diagnosis of AIDS, CHM focuses on relieving symptoms of patients having AIDS-related opportunistic 
infection16. There was no statistical difference in the death rate among the three groups, and it may relate to the 
generally low death rate of patients with HIV.
In China, governments provide patients with free antiviral drug including nucleoside reverse transcriptase 
inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), and protease inhibitor (PI), such as 
inhibitor didanosine (ddI), lamivudine (3TC), stavudine (d4T), zidovudine (AZT, ZDV), nevirapine (NVP), and 
indinavir (IDV). Using a combination of d4T, 3TC and NVP are recommended as the first-line treatment for 
patients who had not received ART. For those patients who had accepted ART before, experts decide whether 
they need to change by considering their condition and personal willingness17.
As a chronic disease, the safety of long-term medication is an important issue that both patients and doctors 
concerned with. In this study, long-term CHM alone or ART combined regimens seemed safety. After the first three 
months of treatment, only patients who used ART alone had a significant increase in the abnormal rate of liver func-
tion. While patients used CHM alone and CHM combined with ART had no significant change in liver function.
The strength of our study was our use of both traditional statistical methods and GEE to analyze longitudinal 
data. This study has some limitations. The CHM database was based on the patients who had agreed to take part 
and who completed the full four years follow up and possibly did not reflect all those taking CHM. There may also 
have been some selection bias with those who accepted CHM as a treatment or as part of their treatment regimen. 
This was not a randomized controlled trial, and therefore, potential selection bias of whether or not to consent to 
the study may have influenced the results.
conclusions
Three therapies appeared to improve CD4 cell counts of patients in the first three years. After three years, CHM 
alone or combined with ART could still improve CD4 cell counts. There was no evidence to suggest CHM could 
decrease mortality. It is noteworthy that compared to patients who only took ART, patients taking CHM were 
more likely to have a steady rise in CD4 cell counts.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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